title: Effects of conditioning intensity in allogeneic stem cell  transplantation for Philadelphia chromosome‑positive acute  lymphoblastic leukemia.
abstract: We retrospectively analyzed the outcomes of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who underwent first allogeneic stem cell transplantation (allo-SCT) at complete remission (CR) with myeloablative conditioning (MAC, n = 31) or reduced-intensity conditioning (RIC, n = 15) between 2001 and 2012. All the patients had received tyrosine kinase inhibitor (TKI)-based chemotherapy prior to allo-SCT. Overall survival (OS) rates (57 vs 63%, p = 0.53), leukemia-free survival rates (50 vs 65%, p = 0.29), and non-relapse mortality rates (39 vs 35%, p = 0.62) at 2 years were similar between the MAC and RIC groups. The minimal residual disease (MRD) status evaluated by sensitive polymerase chain reaction prior to allo-SCT did not influence the OS rate (77 vs 54%, p = 0.28) and leukemia-free survival rate (69 vs 51%, p = 0.48), irrespective of the conditioning intensity. Our data suggest that the RIC regimen may represent a sufficient intensity of therapeutic pre-transplant conditioning for patients with Ph+ALL who have maintained a hematological CR with TKI-combined chemotherapy.
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Takashima
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kamimura
authors.forename: Goichi
authors.initials: G
authors.lastname: Yoshimoto
authors.forename: Shuro
authors.initials: S
authors.lastname: Yoshida
authors.forename: Hideho
authors.initials: H
authors.lastname: Henzan
authors.forename: Ken
authors.initials: K
authors.lastname: Takase
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.forename: Yoshikiyo
authors.initials: Y
authors.lastname: Ito
authors.forename: Yuju
authors.initials: Y
authors.lastname: Ohno
authors.forename: Koji
authors.initials: K
authors.lastname: Nagafuji
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Eto
authors.forename: Takanori
authors.initials: T
authors.lastname: Techima
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D064591:Allografts; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000069439:Dasatinib / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D000069439:Dasatinib